Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3120A |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
1 ml |
Concentrate |
CE/IVD |
ACI3120C |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Reveal modified Citrate pH 6.0 or Diva modified Citrate pH 6.2 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
6 ml |
Ready-to-use |
CE/IVD |
API3120AA |
-
|
Host |
Mouse |
Klon |
SOX11-C1 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Mantle Cell Lymphoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1/κ |
Lokalisation |
Nuclear |
SOX11
|
Biocare Medical |
SOX11-C1 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3120G |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
ACI135A |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
ACI135B |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
1:100 - 1:200 |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
ACI135C |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
7 ml |
Ready-to-use |
RUO |
ALR135G7 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Spirochete infected tissue |
Verdünnung |
- |
Isotyp |
not determined |
Lokalisation |
Corkscrew bacteria |
Spirochete (Treponema pallidum)
|
Biocare Medical |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
API135AA |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
IF |
Isotyp |
Rabbit IgG |
Verdünnung |
Staphylococcus aureus ATCC27660 |
Staphylococcus aureus
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
619-0198 |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
1.0 ml |
Concentrate |
CE/IVD |
Z2727RL |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
7ml |
ready-to-use |
CE/IVD |
Z2727RP |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.5 ml |
Concentrate |
CE/IVD |
Z2727RS |
-
|
Host |
Rabbit |
Klon |
ZR289 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Solitary fibrous tumor. |
Verdünnung |
1:100-200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human STAT6 protein |
Lokalisation |
Cytoplasmic, Nuclear |
STAT6
|
Zeta Corporation |
ZR289 |
0.1 ml |
Concentrate |
CE/IVD |
Z2727RT |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
1.0 ml |
Concentrate |
CE/IVD |
Z2223ML |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
7 ml |
Ready-to-use |
CE/IVD |
Z2223MP |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.5 ml |
Concentrate |
CE/IVD |
Z2223MS |
-
|
Host |
Mouse |
Klon |
N1665 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Adrenal cortical carcinoma. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthesized peptide corresponding to amino acids 220-461 SF-1 protein |
Lokalisation |
Nucleus |
Steroidogenic Factor-1 (SF-1)
|
Zeta Corporation |
N1665 |
0.1 ml |
Concentrate |
CE/IVD |
Z2223MT |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
1 ml |
Concentrate |
CE/IVD |
Z2428ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
7 ml |
Ready-to-use |
CE/IVD |
Z2428MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.5 ml |
Concentrate |
CE/IVD |
Z2428MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM124 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Lung adenocarcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment (around aa241-336) of human SFTPD protein |
Lokalisation |
Cytoplasm |
Surfactant
|
Zeta Corporation |
ZM124 |
0.1 ml |
Concentrate |
CE/IVD |
Z2428MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
MS, RT, BV, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas, Pheochromocytoma |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide of human synaptophysin. |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
0.5 ml |
Concentrate |
RUO |
519-2172 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Reaktivität |
MS, RT, BV, PG |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas, Pheochromocytoma |
Verdünnung |
1:300 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide of human synaptophysin. |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Concentrate |
RUO |
519-2174 |
-
|
Host |
Rabbit |
Klon |
SP11 |
Format |
Concentrate |
Reaktivität |
MS, RT, BV |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas or Pheochromocytoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
0.5 ml |
Concentrate |
RUO |
519-3112 |
-
|
Host |
Rabbit |
Klon |
SP11 |
Format |
Concentrate |
Reaktivität |
MS, RT, BV |
Methode |
F, P, WB |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas or Pheochromocytoma |
Verdünnung |
1:200 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to human Synaptophysin |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zytomed Systems GmbH |
SP11 |
1 ml |
Concentrate |
RUO |
519-3114 |
-
|
Host |
Mouse |
Klon |
27G12 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Pancreas, colon |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Biocare Medical |
27G12 |
6 ml |
Ready-to-use |
CE/IVD |
AVI371G |
-
|
Host |
Mouse |
Klon |
SYP02 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
1 ml |
Concentrate |
CE/IVD |
MOB399 |
-
|
Host |
Mouse |
Klon |
SYP02 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
0.1 ml |
Concentrate |
CE/IVD |
MOB399-01 |
-
|
Host |
Mouse |
Klon |
SYP02 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
0.5 ml |
Concentrate |
CE/IVD |
MOB399-05 |
-
|
Host |
Mouse |
Klon |
SYP02 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Pancreas |
Verdünnung |
ready-to-use |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Diagnostic Biosystems |
SYP02 |
6 ml |
Concentrate |
CE/IVD |
PDM592 |
-
|
Host |
Monospecific Mouse |
Klon |
ZM208 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
1 ml |
Concentrate |
CE/IVD |
Z2544ML |
-
|
Host |
Monospecific Mouse |
Klon |
ZM208 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
7 ml |
Ready-to-use |
CE/IVD |
Z2544MP |
-
|
Host |
Monospecific Mouse |
Klon |
ZM208 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
0.5 ml |
Concentrate |
CE/IVD |
Z2544MS |
-
|
Host |
Monospecific Mouse |
Klon |
ZM208 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Pancreas. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Synthetic peptide within Human Synaptophysin aa 200-300 |
Lokalisation |
Cytoplasm |
Synaptophysin
|
Zeta Corporation |
ZM208 |
0.1 ml |
Concentrate |
CE/IVD |
Z2544MT |
-
|
Host |
Rabbit |
Klon |
SP70 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Breast Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from N-terminus of human tau protein. |
Lokalisation |
Cytoplasm |
TAU
|
Zytomed Systems GmbH |
SP70 |
1 ml |
Concentrate |
RUO |
520-3704 |
-
|
Host |
Mouse |
Klon |
Tau46 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Alzheimer Brain |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
TAU
|
Diagnostic Biosystems |
Tau46 |
0.1 ml |
Concentrate |
CE/IVD |
MOB472-01 |
-
|
Host |
Mouse |
Klon |
Tau46 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Alzheimer Brain |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
TAU
|
Diagnostic Biosystems |
Tau46 |
0.5 ml |
Concentrate |
CE/IVD |
MOB472-05 |
-
|
Host |
Mouse |
Klon |
ZM92 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
1 ml |
Concentrate |
CE/IVD |
Z2402ML |
-
|
Host |
Mouse |
Klon |
ZM92 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
7 ml |
Ready-to-use |
CE/IVD |
Z2402MP |
-
|
Host |
Mouse |
Klon |
ZM92 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
0.5 ml |
Concentrate |
CE/IVD |
Z2402MS |
-
|
Host |
Mouse |
Klon |
ZM92 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
Citrate or EDTA |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human TCL1 protein fragment (around aa 2-109) |
Lokalisation |
Cytoplasm |
TCL1
|
Zeta Corporation |
ZM92 |
0.1 ml |
Concentrate |
CE/IVD |
Z2402MT |
-
|
Host |
Mouse |
Klon |
3A8 |
Format |
Purified |
Methode |
F, IP |
Isotyp |
Mouse IgG2a |
TCR, alpha (T-Cell Receptor)
|
Zytomed Systems GmbH |
3A8 |
100 µg |
Purified |
RUO |
620-0019 |
-
|
Host |
Mouse |
Klon |
3A8 |
Format |
Purified |
Methode |
F, IP |
Isotyp |
Mouse IgG2a |
TCR, alpha (T-Cell Receptor)
|
Zytomed Systems GmbH |
3A8 |
50 µg |
Purified |
RUO |
620-0020 |
-
|
Host |
Hamster |
Klon |
H57-597 |
Format |
Purified |
Methode |
IP, FL |
Isotyp |
Hamster IgG |
Verdünnung |
Affinity purified murine T cell receptor |
TCR, alpha, beta (T-Cell Receptor)
|
Zytomed Systems GmbH |
H57-597 |
250 µg |
Purified |
RUO |
620-0021 |
-
|
Host |
Mouse |
Klon |
R73 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
Rat T blasts and erythrocytes |
TCR, alpha, beta (T-Cell Receptor)
|
Zytomed Systems GmbH |
R73 |
100 µg |
Purified |
RUO |
620-0024 |
-
|
Host |
Mouse |
Klon |
V65 |
Format |
Purified |
Methode |
F, IP, FL |
Isotyp |
Mouse IgG1 |
Verdünnung |
CD3 +ve TCR alpha/beta -ve rat T cell hybridoma line |
TCR, gamma, delta (T-Cell Receptor)
|
Zytomed Systems GmbH |
V65 |
250 µg |
Purified |
RUO |
620-0037 |
-
|
Host |
Mouse |
Klon |
SEN28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thymus |
Verdünnung |
1:10 - 1:50 |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
1 ml |
Concentrate |
CE/IVD |
MOB545 |
-
|
Host |
Mouse |
Klon |
SEN28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thymus |
Verdünnung |
1:10 - 1:50 |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
0.1 ml |
Concentrate |
CE/IVD |
MOB545-01 |
-
|
Host |
Mouse |
Klon |
SEN28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Thymus |
Verdünnung |
1:10 - 1:50 |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant protein corresponding to the amino terminal region of TdT molecule |
Lokalisation |
Nucleus |
TdT (Terminal Desoxynucleotidyl Transferase)
|
Diagnostic Biosystems |
SEN28 |
0.5 ml |
Concentrate |
CE/IVD |
MOB545-05 |
-
|